证券代码：300622 证券简称：博士眼镜 公告编号：2024-078 博士眼镜连锁股份有限公司 关于调整 2021 年限制性股票与股票期权激励计划股票期权 行权价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 博士眼镜连锁股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召开 第五届董事会第七次会议、第五届监事会第七次会议，分别审议通过了《关于调 整 2021 年限制性股票与股票期权激励计划股票期权行权价格的议案》，现将相关 事项公告如下： 一、2021 年限制性股票与股票期权激励计划已履行的相关审批程序 1、2021 年 4 月 20 日，公司第四届董事会第四次会议审议通过了《关于<博 士眼镜连锁股份有限公司 2021 年限制性股票与股票期权激励计划（草案）>及其 摘要的议案》《关于<博士眼镜连锁股份有限公司 2021 年限制性股票与股票期权 激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会办理公司 2021 年限制性股票与股票期权激励计划相关事宜的议案》，公司独立董事对相关 事项发表了意见。同日，公司第四届监事会第 ...

国浩律师（深圳）事务所 致：博士眼镜连锁股份有限公司 关于 博士眼镜连锁股份有限公司 2021 年限制性股票与股票期权激励计划 限制性股票回购价格与股票期权行权价格调整事项 之 法律意见书 深圳市深南大道 6008 号特区报业大厦 42、41、31DE、2401、2403、2405 层 邮编：518034 电话/Tel: (+86)(755) 8351 5666 传真/Fax: (+86)(755) 8351 5333 网址:http://www.grandall.com.cn 二○二四年十一月 国浩律师（深圳）事务所 法律意见书 国浩律师（深圳）事务所 关于 博士眼镜连锁股份有限公司 2021 年限制性股票与股票期权激励计划 限制性股票回购价格与股票期权行权价格调整事项 之 法律意见书 GLG/SZ/A2426/FY/2024-1132 国浩律师（深圳）事务所（以下简称"本所"）接受博士眼镜连锁股份 有限公司（以下简称"公司"）的委托，担任公司 2021 年限制性股票与股票 期权激励计划（以下简称"本次激励计划"）的专项法律顾问。 本 所 律 师 根 据 《 中 华 人 民 共 和 国 公 司 法 》 （ ...

证券代码：300622 证券简称：博士眼镜 公告编号：2024-075 博士眼镜连锁股份有限公司 二、董事会会议审议情况 1、审议通过了《关于调整 2021 年限制性股票与股票期权激励计划限制性股 票回购价格的议案》 表决结果：4 票同意、0 票反对、0 票弃权 关联董事刘之明先生、何庆柏先生、郑庆秋女士为本次激励计划激励对象， 董事 ALEXANDER LIU 先生、LOUISA FAN 女士与激励对象刘开跃先生是一致行动 人，上述董事回避了本议案的表决，其他 4 名非关联董事参与了表决。 鉴于公司于 2024 年 10 月 15 日完成了 2024 年半年度权益分派事项，因此需 对 2021 年限制性股票与股票期权激励计划的限制性股票回购价格进行调整。根 据公司《2021 年限制性股票与股票期权激励计划（草案）》的相关规定及公司 2020 年度股东大会的授权，公司 2021 年限制性股票与股票期权激励计划的回购价格 调整为 7.17 元/股。 本议案已经公司独立董事专门会议审议通过。 1 第五届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或 ...

Investment Rating - The report maintains a rating of "Buy" for the company [6][12]. Core Views - The company's Q3 net profit shows improvement, indicating operational resilience, and the development of smart glasses is a growing trend, with the company actively advancing its layout to benefit first [2]. - Revenue for the first three quarters reached 915 million yuan, a year-on-year increase of 1.09%, while net profit attributable to the parent company was 83 million yuan, down 14.5% [2]. - The forecast for EPS has been adjusted downwards for 2024-2026 to 0.78, 0.91, and 1.05 yuan respectively, with growth rates of 6%, 17%, and 15% [2]. - The target price is set at 31.64 yuan, based on comparable company valuations [2][12]. Financial Summary - Revenue is projected to grow from 962 million yuan in 2022 to 1,528 million yuan in 2026, with a CAGR of approximately 11% [1]. - Net profit attributable to the parent company is expected to increase from 76 million yuan in 2022 to 183 million yuan in 2026, reflecting a significant recovery after a decline in 2023 [1]. - The company's net profit margin is projected to improve from 7.7% in 2022 to 12.1% in 2026 [1]. - The price-to-earnings ratio (P/E) is expected to decrease from 63.50 in 2022 to 26.36 in 2026, indicating a more attractive valuation over time [1]. Industry Insights - The smart glasses market is becoming increasingly competitive, with major players like Meta and Apple making significant advancements [2]. - The company is positioned to leverage its first-mover advantage in the smart glasses sector, having established partnerships with various brands and set up dedicated smart glasses counters in 100 offline stores [2]. - The report highlights the potential for smart glasses to replicate the growth trajectory of TWS earbuds as technology advances and production costs decrease [2].

博士眼镜连锁股份有限公司 第五届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300622 证券简称：博士眼镜 公告编号：2024-073 具体内容详见披露于巨潮资讯网（www.cninfo.com.cn）的相关公告。 三、备查文件 1、《博士眼镜连锁股份有限公司第五届监事会第六次会议决议》。 特此公告。 一、监事会会议召开情况 博士眼镜连锁股份有限公司（以下简称"公司"）第五届监事会第六次会议 通知于 2024 年 10 月 25 日以电子邮件的形式发出，会议于 2024 年 10 月 28 日 上午 11:30 在公司会议室以现场表决方式召开。本次会议应参与表决监事 3 人， 实际参与表决监事 3 人。会议由监事会主席杨晓民先生召集和主持，董事会秘书 丁芸洁女士列席会议。本次会议的召开符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于<2024 年第三季度报告>的议案》 表决结果：3 票同意、0 票反对、0 票弃权 经审议，监事会认为董事会编制和审核公司《 ...

证券代码：300622 证券简称：博士眼镜 公告编号：2024-072 博士眼镜连锁股份有限公司 第五届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 经审议，董事会认为公司《2024 年第三季度报告》的编制和审议程序符合相 关法律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容真实、 准确、完整地反映了公司 2024 年第三季度的实际经营情况，不存在任何虚假记 载、误导性陈述或者重大遗漏。 具体内容详见披露于巨潮资讯网（www.cninfo.com.cn）的相关公告。 三、备查文件 1、《博士眼镜连锁股份有限公司第五届董事会第六次会议决议》。 特此公告。 一、董事会会议召开情况 博士眼镜连锁股份有限公司（以下简称"公司"）第五届董事会第六次会议 通知于 2024 年 10 月 25 日以电子邮件的形式发出，会议于 2024 年 10 月 28 日 上午 10:30 在公司会议室以现场结合通讯表决等方式召开。本次会议应参与表决 董事 9 人，实际参与表决董事 9 人，会议由董事长 ALEXANDER LIU 先生召集和主 持 ...

Financial Performance - The company's revenue for Q3 2024 was ¥314,318,633.69, representing a 2.54% increase year-over-year[2] - Net profit attributable to shareholders for Q3 2024 was ¥31,099,762.48, a slight increase of 0.23% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses for Q3 2024 was ¥27,404,785.61, showing a decrease of 12.33% year-over-year[2] - Total operating revenue for Q3 2024 reached ¥915,266,819.34, a slight increase from ¥905,423,793.77 in Q3 2023, representing a growth of approximately 1.9%[18] - Operating profit for Q3 2024 was ¥103,858,040.01, down from ¥122,151,644.01 in the same period last year, indicating a decrease of about 15%[19] - Net profit for Q3 2024 was ¥82,799,233.94, compared to ¥99,688,950.56 in Q3 2023, reflecting a decline of approximately 16.9%[19] - Basic earnings per share for Q3 2024 were ¥0.48, down from ¥0.57 in Q3 2023, indicating a decrease of approximately 15.8%[20] - Other comprehensive income after tax for Q3 2024 was -¥228,217.17, compared to ¥3,239,930.72 in Q3 2023, indicating a significant decline[20] Assets and Liabilities - Total assets as of September 30, 2024, reached ¥1,284,443,916.97, reflecting a 14.50% increase from the end of the previous year[2] - The total liabilities increased to ¥483,890,002.54 in Q3 2024 from ¥309,486,440.76 in Q3 2023, marking an increase of about 56.3%[18] - Current assets totaled RMB 833,010,196.38, up from RMB 576,920,207.24, marking an increase of approximately 44.4%[17] - Non-current assets decreased to RMB 451,433,720.59 from RMB 544,854,867.37, a decline of about 17.1%[17] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥225,458,103.93, down 9.90% compared to the same period last year[2] - Cash flow from operating activities for Q3 2024 was ¥933,226,854.92, up from ¥917,527,325.91 in Q3 2023, showing a growth of approximately 1.7%[21] - The company reported a net cash flow from operating activities of CNY 225.46 million, down from CNY 250.24 million, a decrease of 9.9%[22] - Net cash outflow from investing activities was CNY 226.23 million, worsening from a net outflow of CNY 157.04 million year-over-year[22] - Cash inflow from investment activities totaled CNY 590.12 million, significantly higher than CNY 103.02 million in the same period last year, indicating a growth of 471.5%[22] - Cash outflow for purchasing fixed assets and intangible assets was CNY 797.66 million, up from CNY 246.40 million, representing an increase of 223.5%[22] - Net cash flow from financing activities was negative at CNY 109.44 million, an improvement from a net outflow of CNY 130.12 million in the previous year[22] - The ending balance of cash and cash equivalents was CNY 81.38 million, a decrease from CNY 191.70 million year-over-year[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,922[10] - Louisa Fan holds 21.92% of shares, totaling 38,420,935 shares[10] - Alexander Liu holds 20.25% of shares, totaling 35,491,665 shares[10] - The total number of restricted shares at the beginning of the period was 58,718,368, with 2,325,954 shares released during the period[12] - The company has a total of 56,548,114 restricted shares remaining at the end of the period[12] - The company’s major shareholders, Louisa Fan and Alexander Liu, are identified as the actual controllers of the company[11] - The company has not reported any changes in the top 10 shareholders due to securities lending or borrowing[11] - The company has not disclosed any related party transactions among other shareholders[11] Dividends - The company approved a cash dividend of RMB 1.60 per 10 shares for the 2024 interim profit distribution, with the record date set for October 14, 2024[14] Inventory and Receivables - Inventory as of September 30, 2024, was ¥234,274,900, an increase of 34.32% from the end of the previous year, primarily due to preemptive stocking[6] - Accounts receivable rose to RMB 74,182,632.26 from RMB 64,348,941.76, indicating an increase of about 15%[16] - Other receivables increased to RMB 69,073,452.53 from RMB 51,611,965.06, showing a rise of about 33.8%[17] Legal Matters - The company is actively pursuing legal action to protect its trademark rights, which is expected to have no significant adverse impact on operations[15] - The company has initiated administrative litigation regarding the trademark disputes, with the court already reviewing the case[15] Accounting Standards - The company did not undergo an audit for the third quarter report[23] - The company will implement new accounting standards starting in 2024, affecting the financial statements[23]

证券代码：300622 证券简称：博士眼镜 编号：2024-12 博士眼镜连锁股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------|-------|---------------------------------------------------|------------|----------------------------------------------------------| | | □ | 特定对象调研 | □ | 分析师会议 | | 投资者关系活动 | □ | 媒体采访 | □ | 业绩说明会 | | 类别 | □ | 新闻发布会 □ | | 路演活动 | | | ☑ | 现场参观 | | | | | □ | 其他 | | | | 参与单位名称 | | 金、时代伯乐（排名不分先后） | | 华创证券、信达澳亚、河床资本、东莞资管、中山资管、金信基 | | | | | | | | | | | | | | 时间 | 2024 | 年 10 月 24 日 | | | | 地点 | | 公司会议室 | ...

证券代码：300622 证券简称：博士眼镜 公告编号：2024-071 博士眼镜连锁股份有限公司 2024 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 每股分红金额不变的原则对分红总额进行调整。 特别提示： 1、博士眼镜连锁股份有限公司（以下简称"公司"或"本公司"）2024 年 半年度权益分派方案为：公司以实施权益分派登记日登记的股份总数为基数，向 全体股东每 10 股派发现金股利人民币 1.60 元（含税），不送红股，不以资本公 积金转增股本。截至本公告披露日，公司总股本为 175,260,670 股，按照每股分 红金额不变的原则，预计派发现金红利 28,041,707.20 元（含税）。 2、本次权益分派实施后除权除息参考价=股权登记日收盘价-每股现金红利 =股权登记日收盘价-0.16 元/股。 1、公司于 2024 年 5 月 22 日召开 2023 年度股东大会审议通过了《关于提请 股东大会授权董事会决定 2024 年中期或春节前利润分配的议案》，授权董事会 全权办理 2024 年中期（包含半年度、前三季度）或春节前利润 ...